Patients & Families
Our Commitment
Every day, more than 500 researchers and staff come to work at Intellia. We are motivated by our mission to develop potentially curative genome editingAlso called gene editing. Genome editing collectively refers to a set of technologies, including CRISPR/Cas9, that can be used to cut and modify DNA. Genome editing uses systems to make the DNA change inside the cell. These cells can be edited in the body (in vivo) or outside the body (ex vivo) from a patient or donor. treatments for people living with severe diseases.
John Leonard, M.D.
Intellia’s President & CEO
“Many of us pursuing work in the biotechnology industry are inspired by the loss of a loved one or someone in our community who is living with a disease.”
